Amadix (Advanced Marker Discovery), a Valladolid, Spain-based biotechnology company, merged with Transbiomed and raised €2m in funding.
Backers included CRB Bio II, a Life Sciences fund managed by CRB Inverbío, which committed €1,5m, and the venture capital firm Inveready, which committed €0,5m. The company also received different public credit financings.
Following the transaction, shareholders in Amadix include:
– CRB Bio II FCR,
– Inveready Seed Capital SCR,
– Fondo Tecnológico Seguranza FCR,
– ADE Capital Sodical SCR, and
– the founders of Transbiomed.
Led by Rocío Arroyo, the company specializes in developing cancer diagnostics, mainly lung, colon and prostate cancers, and intends to use the funds to continue to develop its pipeline and acquire new biomarkers.
FinSMEs
10/02/2013